Frankfurt
25.07.25 | 09:09
0,094 Euro
+7,09 % +0,006
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 3 2024/2025 | 51 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2025 - May 31, 2025. This English version of the Interim Report is a translation of the Swedish version.... ► Artikel lesen | |
| 14.07. | NEXTCELL PHARMA AB: NextCell Highlighted in FUJIFILM's Strategic Vision, According to GEN | 2 | Cision News | ||
| 13.06. | NextCell Pharma AB: All Patients Successfully Treated in ProTrans-Young Study | 325 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") announces today that all patients in the ongoing ProTrans-Young clinical trial have now successfully been treated. This milestone marks the completion... ► Artikel lesen | |
| 02.06. | NEXTCELL PHARMA AB: NextCell Pharma announces outcome of exercise of TO2 and resolves on directed share issues to guarantors | 1 | Cision News | ||
| NEXTCELL PHARMA Aktie jetzt für 0€ handeln | |||||
| 28.05. | NEXTCELL PHARMA AB: NextCell Pharma receives additional declarations of intent regarding exercise of TO2 | 1 | Cision News | ||
| 28.05. | NEXTCELL PHARMA AB: Angela Vollstedt joins NextCell Pharma's Board of Advisors to Strengthen Scientific and Manufacturing Strategy Ahead of Licensing Discussions | 1 | Cision News | ||
| 26.05. | NextCell Pharma AB: NextCell Receives US Patent for MSC Prediction Algorithm | 303 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") is pleased to announce the issuance of a US patent titled "MSC Prediction Algorithm" by the United States Patent and Trademark Office (USPTO). The patent... ► Artikel lesen | |
| 23.05. | NEXTCELL PHARMA AB: NextCell Pharma receives declarations of intent, subscription undertakings and top guarantees regarding exercise of TO2 | 1 | Cision News | ||
| 20.05. | NextCell, Fujifilm Irvine Scientific Enter Strategic Pact | 4 | Contract Pharma | ||
| 20.05. | NextCell Pharma AB: NextCell announces strategic collaboration with Fujifilm Irvine Scientific | 678 | GlobeNewswire (Europe) | NextCell Pharma AB's ("NextCell" or "the Company") has entered into a strategic collaboration with Fujifilm Irvine Scientific Inc. to bring together their core competences in mesenchymal stromal cells... ► Artikel lesen | |
| 19.05. | NEXTCELL PHARMA AB: Eric Strati Joins NextCell Pharma's Board of Advisors to Support Commercial Strategy for ProTrans | 1 | Cision News | ||
| 16.05. | NEXTCELL PHARMA AB: The exercise period for NextCell Pharma's warrants of series TO2 begins today | - | Cision News | ||
| 15.05. | NEXTCELL PHARMA AB: Eight-Year-Old Hugo - Living with Type 1 Diabetes and Participating in the ProTrans Study | 1 | Cision News | ||
| 07.05. | NEXTCELL PHARMA AB: Study published in Nature Medicine shows promising results in Alzheimer's disease - supports the development of ProTrans at NextCell | 2 | Cision News | ||
| 25.04. | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 2 2024/2025 | 96 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 - February 28, 2025. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report.... ► Artikel lesen | |
| 24.04. | NEXTCELL PHARMA AB: NextCell presents detailed analysis of the administrative report from ProTrans-Young | 2 | Cision News | ||
| 23.04. | NEXTCELL PHARMA AB: NextCell Presents Quarterly Report | 4 | Cision News | ||
| 15.04. | NextCell Pharma AB: NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward | 116 | GlobeNewswire (Europe) | NextCell Pharma ("the company" or "NextCell") has published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discusses with Mathias questions regarding the... ► Artikel lesen | |
| 07.04. | NEXTCELL PHARMA AB: Subgroup Analysis: NextCell Presents Preliminary One-Year Results from the Older Age Group in ProTrans-Young | 1 | Cision News | ||
| 28.03. | NEXTCELL PHARMA AB: NextCell's CSO Appointed to the Board of ATMP Sweden | 5 | Cision News |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,252 | +6,46 % | Evotec korrigiert Jahresziel: Was bremst die Aktie aus? | Die Evotec-Aktie ist erneut unter Druck geraten: Nach der überraschenden Senkung der Umsatzprognose für das Geschäftsjahr 2025 fiel der Kurs auf 6,248 EUR - der tiefste Stand seit November 2022. Das... ► Artikel lesen | |
| QIAGEN | 43,870 | +0,52 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 36,230 | +9,09 % | Avidity Biosciences, Inc.: Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping | -- On track for planned BLA submission for del-zota at year end 2025 --
SAN DIEGO, July 23, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,490 | +3,67 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| ARCELLX | 71,31 | +1,48 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 40,820 | -1,97 % | Apogee Therapeutics und der 50-Milliarden-Dollar-Markt | Anfang der Woche hatten wir erstmals über Apogee Therapeutics und dessen jüngste Studienergebnisse berichtet. Weiterhin ergibt sich bei der Aktie eine hochattraktive Gelegenheit, die kurzfristige Kursschwäche... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,070 | -0,98 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
| BIONTECH | 98,15 | 0,00 % | BioNTech SE: BioNTech veröffentlicht am 4. August 2025 Ergebnisse für das zweite Quartal 2025 und informiert über operativen Fortschritt | MAINZ, Deutschland, 21. Juli 2025(Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Montag, den 4. August 2025, die Ergebnisse für das zweite Quartal 2025 veröffentlichen. Darüber hinaus wird... ► Artikel lesen | |
| IMMUNOVANT | 16,930 | -7,59 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| ABSCI | 2,885 | -17,81 % | Cathie Wood's ARK ETF adjusts portfolio, buys ABSCI, sells CRISPR | ||
| SUMMIT THERAPEUTICS | 28,680 | +4,03 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| NUVALENT | 81,47 | -0,74 % | Nuvalent, Inc.: Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC | CAMBRIDGE, Mass., July 21, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted... ► Artikel lesen | |
| SOLID BIOSCIENCES | 7,000 | +4,79 % | Solid Biosciences gets FDA fast track status for heart disease therapy | ||
| ADMA BIOLOGICS | 18,000 | +3,99 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| VALNEVA | 3,234 | -0,49 % | BioTech wird zu Gold: Wer schluckt wen oder was? Auf der Liste sind Evotec, BioNxt, Valneva und Formycon! | Der BioTech-Sektor blickt mit Argusaugen auf das Zinsniveau der Notenbanken. Aktuell allerdings scheint die Inflation noch etwas zu hoch, um massive Senkungen zu erwarten. So hat auch die EZB gestern... ► Artikel lesen |
Das Unternehmen NEXTCELL PHARMA AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,094 Euro und damit +7,09 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXTCELL PHARMA AB finden Sie auf Wallstreet Online.